Category Ranking
98%
Total Visits
921
Avg Visit Duration
2 minutes
Citations
20
Article Abstract
Purpose: Only scarce data are available on the possibility to include radiobiological optimization as part of the dosimetric process in cervical cancer treated with brachytherapy (BT). We compared dosimetric outcomes of pulse-dose-rate (PDR) and high-dose-rate (HDR)-BT, according to linear-quadratic model.
Methods And Materials: Three-dimensional dosimetric data of 10 consecutive patients with cervical cancer undergoing intracavitary image-guided adaptive PDR-BT after external beam radiation therapy were examined. A new HDR plan was generated for each patient using the same method as for the PDR plan. The procedure was intended to achieve the same D high-risk clinical target volume with HDR as with PDR planning after conversion into dose equivalent per 2 Gy fractions (EQD2) following linear-quadratic model. Plans were compared for dosimetric variables.
Results: As per study's methodology, the D high-risk clinical target volume was strictly identical between PDR and HDR plans: 91.0 Gy (interquartile: 86.0-94.6 Gy). The median D intermediate-risk clinical target volume was 62.9 Gy with HDR vs. 65.0 Gy with PDR (p < 0.001). The median bladder D was 65.6 Gy with HDR, vs. 62 Gy with PDR (p = 0.004). Doses to the rectum, sigmoid, and small bowel were higher with HDR plans with a median D of 55.6 Gy (vs. 55.1 Gy, p = 0.027), 67.2 Gy (vs. S 64.7 Gy, p = 0.002), and 69.4 Gy (vs. 66.8 Gy, p = 0.014), respectively. For organs at risk (OARs), the effect of radiobiological weighting depended on the dose delivered. When OARs BT contribution to D doses was <20 Gy, both BT modalities were equivalent. OARs EQD2 doses were all higher with HDR when BT contribution to D was ≥20 Gy.
Conclusion: Both BT modalities provided satisfactory target volume coverage with a slightly higher value with the HDR technique for OARs D2 while intermediate-risk clinical target volume received higher dose in the PDR plan. The radiobiological benefit of PDR over HDR was predominant when BT contribution dose to OARs was >20 Gy.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.brachy.2018.12.009 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Association of distance to diagnosis and area-based social measures with stage at diagnosis among Iowans with HPV-related cancers.
Cancer Causes Control
September 2025
College of Public Health, Iowa Cancer Registry, Epidemiology Department, University of Iowa, Iowa City, IA, USA.
Purpose: Human papillomavirus (HPV) causes oral and anogenital cancers, the incidence of which is increasing. Late-stage diagnosis is associated with increased mortality. Neighborhood-level characteristics and distance to place of diagnosis may impact timely diagnosis.
View Article and Find Full Text PDFCancer treatment delay and 5-year mortality among patients diagnosed with common cancers from 2000 to 2017 in the Philippines.
Jpn J Clin Oncol
September 2025
International Health Program, National Yang Ming Chiao Tung University, No. 155, Sec. 2, Linong St., Beitou Dist., Taipei City 112, Taipei, Taiwan.
Objectives: Treatment delay can adversely affect cancer prognosis and public health. However, previous studies have not examined the association between cancer treatment delay and 5-year mortality risk for various cancer types in a single study population.
Methods: We used retrospective cohort data from 21 740 patients diagnosed with common cancers between 2000 and 2017, with mortality follow-up to 2022, from the Philippines' Department of Health-Rizal Cancer Registry to understand how treatment delay of <30, 30-90, or >90 days was associated with 5-year all-cause mortality risk, by cancer type and stage at diagnosis.
RCN1 Binds KIF14 and Promotes the Malignant Growth of Cervical Cancer Through the PI3K-AKT Pathway.
Int J Gen Med
September 2025
Suzhou Medical College of Soochow University, Suzhou, Jiangsu, People's Republic of China.
Purpose: The fourth most common cause of cancer-related deaths in women is cervical cancer. Though treatment of early-stage cervical cancer is often effective, middle and advanced stage cervical cancer is hard to treat and prone to recurrence. We sought to explore the mechanism underlying cervical cancer progression to identify new therapeutic approaches.
View Article and Find Full Text PDFGlycan dysregulation as one of major metabolic subtypes is associated with TERC overexpression and poor outcomes in cervical cancer.
Front Immunol
September 2025
Department of Medicine, Division of Hematology, Bioclinicum and Center for Molecular Medicine, Karolinska Institute and Karolinska University Hospital Solna, Stockholm, Sweden.
Background: Metabolic reprogramming is an important hallmark of cervical cancer (CC), and extensive studies have provided important information for translational and clinical oncology. Here we sought to determine metabolic association with molecular aberrations, telomere maintenance and outcomes in CC.
Methods: RNA sequencing data from TCGA cohort of CC was analyzed for their metabolic gene expression profile and consensus clustering was then performed to classify tumors into different groups/subtypes.